Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: An update of recent developments

Proteome analysis has emerged as a powerful technology to decipher biological processes. One of the main goals is to discover biomarkers for diseases from tissues and body fluids. However, the complexity and wide dynamic range of protein expression present an enormous challenge to separation technol...

Full description

Saved in:
Bibliographic Details
Published inMass spectrometry reviews Vol. 28; no. 5; pp. 703 - 724
Main Authors Mischak, Harald, Coon, Joshua J, Novak, Jan, Weissinger, Eva M, Schanstra, Joost P, Dominiczak, Anna F
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.09.2009
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Proteome analysis has emerged as a powerful technology to decipher biological processes. One of the main goals is to discover biomarkers for diseases from tissues and body fluids. However, the complexity and wide dynamic range of protein expression present an enormous challenge to separation technologies and mass spectrometry (MS). In this review, we examine the limitations of proteomics, and aim towards the definition of the current key prerequisites. We focus on capillary electrophoresis coupled to mass spectrometry (CE-MS), because this technique continues to show great promise. We discuss CE-MS from an application point of view, and evaluate its merits and vices for biomarker discovery and clinical applications. Finally, we present several examples on the use of CE-MS to determine urinary biomarkers and implications for disease diagnosis, prognosis, and therapy evaluation.
Bibliography:http://dx.doi.org/10.1002/mas.20205
British Heart Foundation Chair and Programme - No. BHF/RG/07/005/23633
EUROTRANS-BIO - No. ETB-2006-016
Inserm
"Direction Régional Clinique" (CHU de Toulouse, France)
ArticleID:MAS20205
InGenious HyperCare - No. LSHM-C7-2006-037093
University of Wisconsin-Madison
Beckman Foundation
Statement of Competing Financial Interest: HM is the founder and co-owner of Mosaiques Diagnostics, which developed the CE-MS technology for clinical application.
Wellcome Trust Cardiovascular Functional Genomics Initiative - No. 066780/2/012
"Deutsche-Jose-Carreras-Leukämie Stiftung" - No. DJCLS 98/05
"Deutsche Forschungsgemeinschaft" - No. DFG Mi-658/01
NIH - No. 1R01GM080148; No. DK078244; No. DK080301; No. DK071802; No. DK061525; No. DK064400
Thermo Fisher
istex:AAA7563779A71467CF99AB9728F18F79E2D9C3A0
ark:/67375/WNG-5RPP5DC7-S
Fondation pour la Recherche Médicale
EURATools - No. LSHG-CT-2005-019015
ANR - No. ANR-07-PHYSIO-004-01
PREDICTIONS - No. 1272568
Statement of Competing Financial Interest: HM is the founder and co‐owner of Mosaiques Diagnostics, which developed the CE–MS technology for clinical application.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-2
ISSN:0277-7037
1098-2787
DOI:10.1002/mas.20205